| Literature DB >> 25250016 |
Pere Berbel1, Daniela Navarro1, Gustavo C Román2.
Abstract
The morphological alterations of cortical lamination observed in mouse models of developmental hypothyroidism prompted the recognition that these experimental changes resembled the brain lesions of children with autism; this led to recent studies showing that maternal thyroid hormone deficiency increases fourfold the risk of autism spectrum disorders (ASD), offering for the first time the possibility of prevention of some forms of ASD. For ethical reasons, the role of thyroid hormones on brain development is currently studied using animal models, usually mice and rats. Although mammals have in common many basic developmental principles regulating brain development, as well as fundamental basic mechanisms that are controlled by similar metabolic pathway activated genes, there are also important differences. For instance, the rodent cerebral cortex is basically a primary cortex, whereas the primary sensory areas in humans account for a very small surface in the cerebral cortex when compared to the associative and frontal areas that are more extensive. Associative and frontal areas in humans are involved in many neurological disorders, including ASD, attention deficit-hyperactive disorder, and dyslexia, among others. Therefore, an evo-devo approach to neocortical evolution among species is fundamental to understand not only the role of thyroid hormones and environmental thyroid disruptors on evolution, development, and organization of the cerebral cortex in mammals but also their role in neurological diseases associated to thyroid dysfunction.Entities:
Keywords: autism; cortical development; evo-devo; hypothyroidism; thyroid hormones
Year: 2014 PMID: 25250016 PMCID: PMC4158880 DOI: 10.3389/fendo.2014.00146
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Significant T3-regulated genes at the transcriptional level found in the cerebral cortex of rodents, involved in cell division and differentiation: relationship with ASD.
| Symbol | Protein | Process | Alteration/disease |
|---|---|---|---|
| Adenylate cyclase-activating polypeptide receptor (PAC1) | Signaling pathway | Decreased second messenger | |
| Caspase 3 | Protease | Apoptosis. Alzheimer’s disease | |
| G1/S-specific cyclin-D1 | Interact with tumor suppressor protein Rb | Abnormal cell cycle G1/S transition | |
| Calporin (actin binding protein; fimbrin type) | Actin associated protein | Abnormal cohesion between parental centrioles | |
| cAMP-responsive element binding protein 1 | Transcription factor | Altered development. ASD | |
| cAMP-responsive element modulator | Transcription factor modulating CREB | Altered development. ASD | |
| β-catenin | Regulates the coordination of cell–cell adhesion and gene transcription | Altered asymmetric cell division, epithelial-to-mesenchymal transition. ASD | |
| Dual specificity tyrosine-phosphorylation- regulated kinase 1A | Nuclear signaling | Abnormal cell proliferation and may be involved in brain development. ASD | |
| Guanine nucleotide-binding protein subunit β-like protein 1 | Six WD40 repeat-containing protein | Abnormal cell cycle progression. Schizophrenia. ASD | |
| Vascular endothelial growth factor receptor 1 | Protein kinase | Abnormal control of cell proliferation and differentiation. ASD | |
| Histone H1t | Compaction of chromatin | Abnormal cell cycle and differentiation | |
| Corticosteroid 11-β-dehydrogenase isozyme 2 | Hydrolysis of cortisol | Cortisol induction of growth-inhibition and/or pro-apoptosis embryonic development | |
| Mitogen-activated protein kinase 1 (ERK2) | CREB1 phosphorylation signaling pathway | ASD | |
| Regulator of G-protein signaling 3 | Ephrin-B signaling pathway | Early cell cycle exit and precocious differentiation |
.
Significant T3-regulated genes at the transcriptional level found in the cerebral cortex of rodents, involved in memory and behavior: relationship with ASD.
| Symbol | Protein | Process | Alteration/disease |
|---|---|---|---|
| Adenylate cyclase type 8 | G-protein associated enzyme | Abnormal cAMP signaling | |
| ADRBK2 | β-adrenergic receptor kinase 2 (GRK3) | G-protein-coupled receptor kinase 3 | Abnormal dopamine metabolism. Schizophrenia and bipolar disorder |
| Calbindin-D28k | Calcium-binding protein | Abnormal synaptic plasticity and long-term potentiation. ASD | |
| Calcium/calmodulin-dependent protein kinase type IV | CREB phosphorylation signaling pathway | ASD | |
| cAMP-responsive element binding protein 1 | Transcription factor | Altered development. ASD | |
| cAMP-responsive element modulator | Transcription factor modulating CREB | Altered development. ASD | |
| D site of albumin promoter (albumin D-box) binding protein | Transcription factor | Abnormal spatial learning and enhanced susceptibility to kainate-induced seizures. Epilepsy, schizophrenia, and bipolar disorder | |
| G-protein-coupled receptor kinase 5 | Signal transduction | Memory impairment. Alzheimer’s disease | |
| Homer protein homolog 1 | Major component of postsynaptic density | Abnormal synaptic plasticity and long-term potentiation. ASD | |
| 5-HT7 receptor | Neuroreceptor | Abnormal learning and memory. Neuropsychiatric disorders. ASD | |
| Mitogen-activated protein kinase 1 (ERK2) | CREB phosphorylation signaling pathway | ASD | |
| Nitric oxide synthase 1 | Neurotransmitter, signaling pathway | Abnormal signaling pathway. ASD | |
| Nuclear receptor related 1 protein (NURR77) | Transcription factor | Abnormal synaptic plasticity in the hippocampus. Altered long-term potentiation. Schizophrenia | |
| Neurotensin | Neuropeptide | Abnormal modulation of dopamine signaling. ASD | |
| Parvalbumin | Calcium-binding protein | Alzheimer’s disease and nervous system disorders. ASD |
.
Significant T3-regulated genes at the transcriptional level found in the cerebral cortex of rodents, involved in neurotransmission: relationship with ASD.
| Symbol | Protein | Process | Alteration/disease |
|---|---|---|---|
| Adenylate cyclase-activating polypeptide receptor (PAC1) | Signaling pathway | Decreased second messenger | |
| Calcium channel, voltage-dependent, γ subunit 8 | Transmembrane AMPA receptor regulatory protein (TARP) | Altered long-term potentiation | |
| Calcium/calmodulin-dependent protein kinase type IV | CREB phosphorylation signaling pathway | ASD | |
| cAMP-responsive element binding protein 1 | Transcription factor | Altered development. ASD | |
| cAMP-responsive element modulator | Transcription factor modulating CREB | Altered development. ASD | |
| Huntingtin-associated protein 1 | Interacts with huntingtin and cytoskeletal proteins | Abnormal vesicular trafficking and organelle transport | |
| Homer protein homolog 1 | Major component of postsynaptic density | Abnormal synaptic plasticity and long-term potentiation. ASD | |
| Histamine H3 receptors | Signal transduction | Abnormal presynaptic inhibition of neurotransmitter release | |
| Potassium voltage-gated channel subfamily C member 1 | Membrane channel | Abnormal repolarization of cortical interneurons | |
| ATP-sensitive inward rectifier potassium channel 10 | Membrane channel | Abnormal repolarization. Epilepsy, ataxia, and deafness. ASD | |
| Potassium channel subfamily K member 2 (TREK1) | Membrane channel | Abnormal neuroprotection against epilepsy and brain and spinal cord ischemia | |
| Potassium voltage-gated channel subfamily S member 2 | Membrane channel | Abnormal repolarization | |
| Potassium channel subfamily T, member 2 | Membrane channel | Abnormal repolarization epilepsy, Alzheimer disease | |
| Mitogen-activated protein kinase 1 (ERK2) | CREB phosphorylation signaling pathway | ASD | |
| Neurogranin | Calmodulin-binding protein. component of postsynaptic density | Abnormal synaptic plasticity and long-term potentiation. Schizophrenia. ASD | |
| Neurotensin | Neuropeptide | Abnormal modulation of dopamine signaling. ASD | |
| Protein kinase C and casein kinase substrate in neurons protein 2 | Binding to endocytic proteins | Arrested endocytosis | |
| Platelet-activating factor acetylhydrolase IB subunit α (Lis1) | Interacts with dynein and VLDLR | Abnormal signaling. Lissencephaly. ASD | |
| Vesicular glutamate transporter 1 (VGLUT1) | Synaptic vesicle membrane protein | Abnormal neurotransmission neuropsychiatric disorders. ADHD, and schizophrenia. ASD |
.
Figure 1Reduced development of cortical maps in developmental hypothyroidism. (A) Cartoon showing the posteromedial barrel subfield of the primary somatosensory cortex in the brain of a rat. Note the correspondence between mysticial vibrises and the barrels of the posteromedial barrel subfield. (B) Brain dorsal views at P40 of control (C) and MMI pups. (C) Computer reconstruction from photomicrographs of serial tangential sections through layer IV, showing cytochrome oxidase labeling in the barrel cortex of normal and hypothyroid rats. Note the reduced tangential extension of the cytochrome oxidase labeling in hypothyroid with respect to normal rats. (D) Area measurements in normal and hypothyroid rats. The dorsal view brain area was, on average, 24% smaller in hypothyroid rats (upper). A similar reduction (on average, 27%) was observed in the PMBSF tangential area (lower). (E) Photomicrographs of cresyl violet stained coronal sections showing the cytoarchitecture of the barrel cortex of the primary somatosensory cortex at P40 in control (C) and transient MMI treated pups (MMI treatment begun at E12 and finished at E15). Borders between layers (horizontal lines) are clear-cut in C whereas they are more blurred in MMI12 pups. In layer IV of C and dMMI pups, barrels (arrow) are normal and well-defined and demarcated by septae (arrowheads). In contrast, barrels in layer IV of MMI1 pups are not seen. In developmentally hypothyroid pups there is a 10–15% reduction in the cortical thickness of MMI pups compared to controls. (A) Modified from Berbel and Morreale de Escobar (57). (C,D) Modified from Berbel et al. (192). (E) Modified from Ausó et al. (158).
Significant T3-regulated genes at the transcriptional level found in the cerebral cortex of rodents, involved in cytoskeleton organization and cell migration: relationship with ASD.
| Symbol | Protein | Process | Alteration/disease |
|---|---|---|---|
| Apolipoprotein E receptor 2 (Lrp8) | Reelin signaling pathway | Alzheimer, major depressive disorder | |
| Calreticulin | Endoplasmic reticulum calcium-binding protein | Abnormal calcium storage in the hippocampus. Alzheimer’s disease | |
| cAMP-responsive element binding protein 1 | Transcription factor | Altered development. ASD | |
| cAMP-responsive element modulator | Transcription factor modulating CREB | Altered development. ASD | |
| Cathepsin S | Protease | Abnormal microglial function | |
| Disabled-1 | Reelin signaling pathway | Abnormal migration. Alzheimer’s disease, temporal lobe epilepsy. ASD | |
| Dynein light chain 1, cytoplasmic | Microtubule associated protein | Abnormal intracellular transport and motility | |
| Fibromodulin | Proteoglycan that sequesters TGF-β into the extracellular matrix | Abnormal regulation of proliferation and differentiation of hippocampal granule neurons | |
| Fibronectin | Extracellular matrix protein | Abnormal cell adhesion, growth, migration, and differentiation. ASD | |
| G-protein α subunit (Gs-α) | Signaling pathway | ASD. ADHD | |
| Chaperonin (HSP60) | Chaperone | Prevent traumatic brain injury | |
| Mitogen-activated protein kinase 1 (ERK2) | CREB phosphorylation signaling pathway | ASD | |
| Neurofilament protein (heavy, medium, and light) | Intermediate filaments | Abnormal neuronal cytoskeleton. ASD | |
| Nephroblastoma overexpressed | Extracellular matrix protein that binds to integrin receptors | Abnormal cell adhesion, migration, proliferation, differentiation,and survival | |
| Opioid-binding protein/cell adhesion molecule | Cell adhesion molecule | Abnormal proliferation and growth of cortical astrocytes | |
| Platelet-activating factor acetylhydrolase IB subunit α (Lis1) | Interact with dynein and VLDLR | Lissencephaly. ASD | |
| Reelin | Extracellular matrix protein | Abnormal migration. Alzheimer’s disease, temporal lobe epilepsy. ASD | |
| Heat shock protein 47 | Chaperone | Abnormal collagen binding. ASD | |
| Slit homolog 1 and 2 proteins | Extracellular matrix protein. Chemorepulsive signal | Abnormal axon guidance. Abnormal angiogenesis | |
| Transforming growth factor-β 2 | Extracellular matrix protein | Abnormal regulation of proliferation and differentiation of hippocampal granule neurons | |
| Tropomyosin α-1 chain | Actin associated protein | Abnormal neuronal cytoskeleton | |
| Very-low-density-lipoprotein receptor | Reelin signaling pathway | Abnormal migration. Alzheimer’s disease, temporal lobe epilepsy. ASD |
.
Figure 2Abnormal neuronal radial and tangential migration, inhibitory local circuits and increased audiogenic seizures in developmental hypothyroidism and hypothyroxinemia. (A,B) Photomicrographs of NeuN-immunostained coronal sections of the primary somatosensory cortex (A) and hippocampal CA1 (B) in LID + KI (rats fed low iodine diet plus approximately 10 μg iodine per day, during gestation and postnatally) and LID (rats fed low iodine diet) progeny at P40. The number of NeuN-labeled neurons increases both in subcortical white matter [wm (A)] and in strata oriens (or) and alveus [al (B)] of hippocampal CA1 of LID pups as compared with LID + KI pups. (C) GFAP- and CNP-positive astrocytes (left panel) and oligodendrocytes (right panel), respectively (arrowheads), and BrdU-positive nuclei (arrows) are shown in layer V of C and LID pups. LID rats received single BrdU injections at E14, E15, and E16. Note that both GFAP-positive astrocytes and CNP-positive oligodendrocytes are BrdU-negative. (D) Low power fluorescent photo- micrograph collage illustrating the tangential distribution of GFP-MGE control migrating neurons (control explant, CE) in wild control flat cortical mounts at E15 (control cortex, CCx; left), and GFP-MGE hypothyroxinemic migrating neurons (3dMMI10) in hypothyroxinemic flat cortical mounts (3dMMI10Cx; right). Note that migrating neurons toward the medial (M) region in the hypothyroxinemic cortical mount (right) expand less than those migrating in the control cortical mount (left). 3dMMI10 rats received MMI treatment from E10 to E12. (E) Photomicrographs through layer V of the auditory cortex immunostained for parvalbumin in normal (C) and hypothyroid (MMI treatment from E14 onward) rats. In normal rats, immunoreactive cells, processes and perisomatic puncta can be seen. In MMI rats, immunoreactive cells, processes and perisomatic puncta can also be seen but they are less prominent than in normal rats. (F) Responses of C and 3dMMI12 (MMI treatment from E12 to E15) pups to an acoustic stimulus. Histograms on the left correspond to the proportion (median with 25th and 75th percentiles) of pups responding with wild runs and with wild runs followed by a seizure, respectively. Graphs on the right represent the cumulative frequency of pups from the same groups that respond with wild runs alone or followed by a seizure, respectively, at the intervals after onset of the stimulus that are shown in the abscissa. (*) Indicates a statistically significant difference compared with control. (A–C) Modified from Lavado-Autric et al. (164). (D) Modified from Cuevas et al. (159). (E) Modified from Berbel et al. (211). (F) Modified from Ausó et al. (158).
Figure 3Thyroid hormones affect connectivity, maturation, and function of the cerebral cortex. (A,B) Collages from confocal photo- micrographs (taken with the ×20 objective) showing double immunolabeling for Camk4 [red; (A)] and Nurr1 [green; (B)] in the parietal cortex of P10 control (C), LMH (pups born to dams thyroidectomized at E16), and MMI (MMI treatment starting at E10) pups. Most of Camk4-immunoreactive neurons were located in layers II–IV and upper layer V. Numerous Camk4-immunoreactive neurons can be seen in layer VIb of P10LMH and P10MMI pups (arrows) compared with P10C pups. At P10, about 60% of Camk4-immunoreactive neurons of layer VIb are also Nurr1-immunoreactive. (C) Photomicrographs of coronal sections of the parietal cortex showing NeuN-immunoreactive neurons in C and LMH pups at P15. At P15, the border between the subplate and adjacent layer VI is more clear-cut in LMH than in C pups, showing that a remaining subplate is still present. (D) Photomicrographs of flattened neocortex tangential sections showing 5-HT immunostaining in the posteromedial barrel subfield of the parietal cortex of C and MMI rats at P4 and P15. At P4, heavily immunostained barrels can be seen. Decay of 5-HT labeling occurs by P11 in C and by P16 in MMI rats. Note that in P15C rats, no barrels were immunostained, whereas in P15MMI rats, they are still immunopositive. (E) Photomicrographs of coronal sections of the area CA3 of the hippocampus showing the Zn-labeling of mossy fibers in C and LMH pups at P40. Note the heavier labeling of mossy fibers in the stratum oriens (arrowhead) of CA3 in C compared with LMH pups. (F) Confocal deconvoluted images of vesicular glutamate transporter type 1 (VGluT1, which labels excitatory buttons) of the stratum radiatum (rm) in CA3 in C and MMI rats at P50, labeling mossy fiber buttons. Note the decreased density of immunoreactive buttons in P50MMI pups compared to controls. (G) Photomicrographs of coronal sections from P4 and P7 MMI rats that had the lipophilic carbocyanine DiI tracer (1,1′-dioctadecyl-3,3,3′,3′- tetramethylindocarbocyanine perchlorate) implanted in the ventro-basal thalamic nucleus. At P4, DiI-labeled thalamic afferents enter the somatosensory cortex, and form clusters in layer IV. At P7, collaterals in layer IV form more dense clusters than at P4. These images show that hypothyroid thalamic axons reach their somatosensory target areas as in normal rats. (H) Coronal views of thalamocortical terminal arbors in layer IV in the posteromedial barrel subfield of C and MMI rats at P60. The barrel limit is marked with dashed lines. Note that in MMI rats terminal arbors have shorter and tortuous branches. (I) Histograms representing mean values for the number of axon segments per terminal (upper), segment length (middle), and buttons per segment (bottom) in C (white bars) and MMI (black bars) rats for each segment order. Note that in general MMI mean values are lower. (J,K) Western blots obtained from the hippocampus of C and LMH pups at P40, immunolabeled for ERK2, pERK1, and pERK2 (J) and pATF1, pCREB, and CREB (K). Histograms showing that the pERK1/ERK2 and pERK2/ERK2 (J) and pCREB/pATF1 and pCREB/CREB (K) ratios are reduced by 44.4, 42.9, 59.1, and 66.7%, respectively, in LMH compared with C pups. (L) Histogram showing step-down latencies in seconds at 1, 3, and 24 h after the initial foot shock in C and LMH pups at P39. Pups from LMH dams show 24.9% reduction in the step-down latency at 1 h after the foot shock. (J–L) Error bars represent ± SD; n.s., no significant differences; *P < 0.001 for LMH compared with C group. (A,B) Modified from Navarro et al. (239). (C,E,J,K,L) Modified from Berbel et al. (169). (D,G,H,I) Modified from Ausó et al. (246).
Significant T3-regulated genes at the transcriptional level found in the cerebral cortex of rodents, involved in neurite growth, guidance, branching, and maturation: relationship with ASD.
| Symbol | Protein | Process | Alteration/disease |
|---|---|---|---|
| Ankyrin-3 | Cytosol protein that interacts with voltage-gated sodium channels and cytoskeletal proteins | Abnormal clustering of voltage-gated sodium channels at the axon hillock and node of Ranvier abnormal action potential firing. ASD | |
| Aristaless-related homeobox | Transcription factor | X-linked intellectual disability, epilepsy, lissencephaly, agenesis of the corpus callosum. ASD | |
| Brain-derived neurotrophic factor | Extracellular signal | Abnormal synaptic structure, function, and plasticity. Fragile X syndrome. ASD | |
| Calcium/calmodulin-dependent protein kinase type IV | CREB phosphorylation signaling pathway | ASD | |
| Chimerin 1 (GTPase-activating protein) | Signal transduction | Abnormal axon pruning | |
| Contactin-4 | Cell adhesion molecule | Abnormal connectivity in the developing nervous system. ASD | |
| cAMP-responsive element binding protein 1 | Transcription factor | Altered development. ASD | |
| cAMP-responsive element modulator | Transcription factor modulating CREB | Altered development. ASD | |
| Vascular endothelial growth factor receptor 1 | Protein kinase. Signal transduction | Abnormal control of cell proliferation and differentiation. ASD | |
| Fibronectin | Extracellular matrix protein | Abnormal cell adhesion, growth, migration, and differentiation. ASD | |
| Huntingtin-associated protein 1 | Interacts with huntingtin and cytoskeletal proteins | Abnormal vesicular trafficking and organelle transport | |
| Kruppel-like factor 9 | Transcription factor | Altered development of neurons | |
| Mitogen-activated protein kinase 1 (ERK2) | CREB phosphorylation signaling pathway | ASD | |
| Neurofilament protein (heavy, medium, and light chains) | Intermediate filaments | Abnormal neuronal cytoskeleton. ASD | |
| Nitric oxide synthase 1 | Neurotransmitter, signaling pathway | Abnormal signaling pathway. Neuroglial inflammation. ASD | |
| Plexin-A2 | Semaphorin co-receptor | Abnormal axon guidance. Schizophrenia, anxiety | |
| Semaphorin-3B | Signal transduction | Abnormal axon guidance | |
| Slit homolog 1 and 2 proteins | Extracellular matrix protein. Chemorepulsive signal | Abnormal axon guidance. Abnormal angiogenesis | |
| Transforming growth factor-β 2 | Extracellular signaling protein | Abnormal regulation of proliferation and differentiation of hippocampal granule neurons |
.
Significant T3-regulated genes at the transcriptional level found in the cerebral cortex of rodents, involved in synaptogenesis and plasticity: relationship with ASD.
| Symbol | Protein | Process | Alteration/disease |
|---|---|---|---|
| Annexin A6 | Calcium-binding protein | Abnormal vesicle aggregation and fusion in the hippocampal neuron’s axon initial segment | |
| Ca(2+)-ATPase | Plasma membrane calcium-ATPase | Abnormal translocation of calcium to the endoplasmic reticulum in hippocampal neurons. ASD | |
| Brain-derived neurotrophic factor | Synaptic structure, function, and plasticity. fragile X syndrome autism | Abnormal synaptic structure, function, and plasticity. Fragile X syndrome. ASD | |
| Calcium/calmodulin-dependent protein kinase type IV | CREB phosphorylation signaling pathway | ASD | |
| Contactin-4 | Cell adhesion molecule | Abnormal connectivity in the developing nervous system. ASD | |
| cAMP-responsive element binding protein 1 | Transcription factor | Altered development. ASD | |
| cAMP-responsive element modulator | Transcription factor modulating CREB | Altered development. ASD | |
| Exocyst complex component 7 | Rho3 signaling | Abnormal cell polarity, regulation of actin polarity and transport of exocytic vesicles | |
| Huntingtin-associated protein 1 | Interacts with huntingtin and cytoskeletal proteins | Abnormal vesicular trafficking and organelle transport | |
| Histamine H3 receptors | Signal transduction | Abnormal presynaptic inhibition of neurotransmitter release | |
| Mitogen-activated protein kinase 1 (ERK2) | CREB phosphorylation signaling pathway | ASD | |
| Nuclear receptor related 1 protein (NURR77) | Transcription factor | Abnormal synaptic plasticity in the hippocampus. Altered long-term potentiation. Schizophrenia | |
| Neurogranin | Calmodulin-binding protein. Component of postsynaptic density | Abnormal synaptic plasticity and long-term potentiation. Schizophrenia. ASD | |
| Platelet-activating factor acetylhydrolase IB subunit α (Lis1) | Interacts with dynein and VLDLR | Lissencephaly. ASD | |
| Phosphatidylinositol binding clathrin assembly protein | Coated vesicles | Abnormal coated vesicles. Alzheimer’s disease | |
| Slit homolog 1 and 2 proteins | Extracellular matrix protein. Chemorepulsive signal | Abnormal axon guidance. Abnormal angiogenesis | |
| Synaptosomal-associated protein 23 | SNARE associated protein | Abnormal exocitosis | |
| Sorting nexin 16 | Membrane associated protein | Protein sorting | |
| Sequestosome-1 | Ubiquitin binding protein | Abnormal regulation of the nuclear factor kappa-B (NF-κB) signaling pathway | |
| Synaptotagmin-2 | Synaptic vesicles docking | Abnormal exocitosis | |
| Synaptotagmin-like protein 5 | Synaptic vesicles docking. Marker for parvalbumin immunoreactive buttons | Abnormal exocitosis | |
| Transforming growth factor-β 2 | Extracellular signaling protein | Abnormal regulation of proliferation and differentiation of hippocampal granule neurons | |
| VAMP4 | Vesicle-associated membrane protein 4 (synaptobrevin) | Synaptic vesicles docking | Abnormal exocitosis |
.